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A 19-year-old female with Systemic Lupus Erythematosus (SLE) presented with ischemia of her left hand 
following trauma. Medical therapy was initiated but failed to improve her symptoms, and revision amputation 
was ultimately performed. The patient’s final diagnosis was digital ischemia due to secondary Raynaud’s 
Phenomenon (RP). The authors discuss diagnosis, complications, and treatment of this relatively uncommon 
disorder.  The  authors  report  this  case  in  order  to  discuss  how  secondary  RP  can  be  complicated  by 
ischemia and the multidisciplinary approach that needs to take place to prevent the latter from occurring. 
[WestJEM.2008;9:43-45.]
intrOdUctiOn
Raynaud’s phenomenon (RP) presents as a challenging 
disease for Emergency Physicians (EP) due to its variability 
in presentation, largely variable medical treatments, and 
risk of significant morbidity. The disease is described 
as an episodic vasospasm of peripheral arteries, causing 
pallor, cyanosis, and at times, subsequent ischemia. It was 
first described by Maurice Raynaud in 1862 as a localized 
“syncope.”1 Primary RP is idiopathic, and secondary RP 
occurs in association with an underlying disease, usually a 
mixed connective tissue disorder (MCTD). The diagnosis is 
based solely on the clinical presentation since there are no 
specific tests to detect primary RP. Prevalence is estimated 
between 3-5% in the general population.2 Despite its high 
frequency, the majority of available therapies have not been 
validated in randomized controlled trials (RCT).
case repOrt
A 19-year-old female was admitted to the hospital 
because she had ongoing ischemia to her left index and small 
fingers. Forty hours before admission, the patient suffered 
trauma to her fingertips when she caught her hand in a car 
door. Thirty-five hours before this presentation, the patient 
was seen in another emergency room and was noted to have 
a bluish discoloration to her fingertips with a history of 
systemic lupus erythematosus. She was diagnosed with RP 
and given amlodipine and aspirin. A few hours later, without 
relief of her symptoms and worsening pain, the patient was 
transferred for higher level of care to a second emergency 
department.
Upon arrival, the patient was afebrile with stable vital 
signs, including a temperature of 98°F, blood pressure of 
125/92 mmHg, pulse of 113, respiratory rate of 18, O2 
saturation of 97% in room air. She was very emotional and 
anxious and expressed a pain level of 10 out of 10. Her left 
hand showed a purplish-blue discoloration and edema to the 
fourth and fifth digits, accompanied by bullae on the ulnar 
surface of her small finger (Figure 1). She was tender to 
palpation along the flexor sheath, but both flexor digitorum 
profundus and superficialis were intact. Pulse oximetry to the 
affected digits was zero, and she had decreased perception to 
light touch. 
The patient was given benzodiazepines and pain 
medication. Orthopaedics was quickly involved on the case 
and an angiogram ordered. Rheumatology upon consultation 
added solumedrol, and the patient was started on an 
epoprostenol drip. 
Left upper extremity angiogram findings included a patent 
left axillary, brachial, ulnar, radial, deep and superficial palmar 
arches, common and proper digital arteries 1-3. There was 
complete occlusion of proper digital arteries for the fourth and 
fifth digits. There was no response to intra-arterial vasodilator 
and the patient was deemed an unlikely candidate for lytic 
therapy secondary to the distal nature of the occlusion.Western Journal of Emergency Medicine                                        44                                                Volume IX, n o . 1  :  January 2008
Figure 1.  Necrotic fourth and fifth digits, five days after presentation 
of SLE patient with secondary Raynaud’s phenomenon
 
After five days of epoprostenol drip with minimal 
improvement in her symptoms, the patient was scheduled 
for revision amputation. Final pathology diagnosis was 
necrosis, mixed inflammation consistent with gangrene due to 
secondary RP.
discUssiOn
Secondary RP is less common than primary RP and occurs 
in association with an underlying disease, typically connective 
tissue, neurovascular, hematological, or drug-induced disorder.3 
While primary Raynaud phenomenon (RP) rarely leads to 
complications, secondary RP, when associated with a mixed 
connective tissue disease (MCTD), can quickly progress to 
catastrophic ischemic events resulting in the loss of fingers, 
toes, and even limbs.4 Timely therapeutic intervention is 
therefore required. Primary and secondary RP appear to be 
in a continuum. In one study, as many as 20% of participants 
followed prospectively were later diagnosed with a MCTD.5 
Determining the root cause of a Raynaud crisis can be difficult, 
and emergent treatment may be challenging due to lack of 
clearly effective therapy. Therapeutic measures have included a 
range from avoiding triggers to vasodilator drugs or anti-platelet 
aggregation drugs to spinal cord stimulation and surgery. 
Treatment should be individualized for every patient depending 
on disease severity.
Conservative treatment for RP includes warming and 
stress reduction,2 however, we found no satisfactory RCTs on 
the effects of warming. Six small RCTs found that nifedipine 
reduced the frequency and severity of attacks over 4-12 weeks 
compared with placebo, and was rated by participants as more 
effective than placebo in improving overall symptoms. The 
participants experienced an average of 2.8 to 5.0 fewer attacks 
per week and a 33% reduction in severity. It was found that 
nifedipine was associated with higher rates of adverse effects 
compared with placebo, causing several participants to drop 
out of every study. Adverse effects include flushing, headache, 
edema, and tachycardia.6 
The use of aspirin and dipyridamole in patients with 
secondary RP has been studied in at least two controlled trails. 
Neither demonstrated any significant effect.7,8 Grader-Beck 
and Wigley recommend that patients with MCTD be placed 
on anti-platelet therapy with 81 mg of aspirin daily, unless 
there is a contraindication. They also recommend the use 
of heparin for 24 to 72 hours for patients who have rapidly 
advancing ischemic disease, but do not recommend chronic 
anticoagulation, despite the fact that this has not been studied.2 
A recent study demonstrated the benefit of low molecular 
weight heparin for symptomatic improvement in primary and 
secondary RP.9 
When ischemia progresses rapidly and fails to respond to 
standard vasodilatory therapy, intravenous iloprost, alprostadil, 
or epoprostenol may be given.2 Similar results in a meta-
analysis were obtained for intravenous infusions of iloprost in 
patients with secondary RP associated with systemic sclerosis. 
In addition, intravenous infusions of iloprost improved healing 
of fingertip ulcers in patients with systemic sclerosis. 
Small single randomized controlled trials include 
angiotensin II-receptor type 1 antagonists (losartan), the 
calcium channel blockers felodipine and amlodipine, serotonin-
reuptake-inhibitors (fluoxetine) and phosphodiesterase-V-
inhibitors (sildenafil, vardenafil). However, the results for these 
promising substances have to be confirmed in long-term trials 
with larger patient numbers.10,11,12, 13 
When medical therapy fails, several surgical interventions 
can be considered. These include proximal or distal 
(digital) sympathectomy and arterial reconstruction. Distal 
sympathectomy is associated with a lower complication rate 
than proximal sympathectomy, but the long-term outcome 
has not been well-documented.14,15 As with other vasodilator 
therapy, sympathectomy is less effective in patients who 
have secondary RP.2,16 Amputation of digits appears to occur 
infrequently and is usually reported as individual cases.17,18  
If there is evidence of larger vessel occlusive disease, 
such as has been reported at the level of the ulnar or radial 
arteries, vascular reconstruction can be performed successfully 
with vein grafts.4 Therefore, all patients who present with 
a critical ischemic crisis should have a careful assessment 
to detect any correctable macrovascular disease. To further 
define the magnitude of larger vessel disease in these cases, 
arterial doppler studies, magnetic resonance angiography, or 
angiography can be used.2
When associated with MCTD, RP requires aggressive 
diagnostics and initial therapy to decrease arterial vasospasm. 
Management of this disease requires a multidisciplinary effort 
in the coordination of a sound treatment plan for without this 
focus, even minor trauma may result in digital amputation.
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